

Global Formulation Development CDMO Supply, Demand and Key Producers, 2026-2032

<https://marketpublishers.com/r/G494E27FD56EEN.html>

Date: June 2026

Pages: 167

Price: US\$ 4,480.00 (Single User License)

ID: G494E27FD56EEN

Abstracts

The global Formulation Development CDMO market size is expected to reach \$ 29907 million by 2032, rising at a market growth of 6.0% CAGR during the forecast period (2026-2032).

Formulation Development CDMO refers to a contract research and manufacturing organization that provides pharmaceutical companies with end-to-end outsourcing services for drug formulation, from formulation design to finished product manufacturing. Its core mission is to combine active pharmaceutical ingredients (APIs) and excipients to develop stable, safe, effective, and scalable final dosage forms, such as tablets, capsules, injections, and inhalers. Services encompass pre-formulation studies (determination of API physicochemical properties and excipient compatibility), formulation screening and optimization, process development (such as wet granulation, hot melt extrusion, and aseptic filling), analytical method development, stability studies, and GMP-compliant clinical sample and commercial batch production. Its value lies in helping clients accelerate formulation development, reduce upfront infrastructure and personnel investment, and overcome technical bottlenecks associated with poorly soluble drugs, complex injections, or special dosage forms. It is a crucial translational step from drug candidate compounds to clinical trials and the market.

The global Formulation Development CDMO market is dominated by Europe and the US, with Asia catching up. North America leads with its mature biopharmaceutical ecosystem and complex formulation (liposomes, nanoparticles) technology, with Thermo Fisher and Catalent dominating the high-end market; however, overcapacity and price competition are emerging. Europe, relying on companies like Lonza with its strong foundation in oral solid dosage forms and sterile injectables, benefits from strong demand from small and medium-sized biotechnology companies; however, energy

costs and fragmented regulations constrain expansion. China, represented by WuXi AppTec and Asymchem, is gaining market share in conventional oral and injectable dosage forms thanks to cost advantages and rapid delivery capabilities, and is accelerating its penetration into complex formulations; however, the quality of excipients and reliance on imported high-end equipment remain weaknesses. Japan has solid technology in transdermal patches and microsphere formulations, but its CDMO scale is relatively limited due to slow growth in its domestic market and a low proportion of outsourced new drug development. Future trends include: continuous manufacturing replacing batch production processes, AI-assisted formulation design shortening development cycles, and explosive demand for novel formulations such as gene therapy vectors and mRNA vaccines. The main obstacles include: high failure rates in the development of complex formulations, monopolies in the supply of key excipients, and increased compliance costs due to regulatory differences among countries under global multi-center filings. Dynamically, leading companies are building differentiated barriers through mergers and acquisitions and technology licensing (such as liposome platform licensing), while extending their service chains to both early-stage R&D and commercialization.

This report studies the global Formulation Development CDMO demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Formulation Development CDMO, and provides market size (US\$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Formulation Development CDMO that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Formulation Development CDMO total market, 2021-2032, (USD Million)

Global Formulation Development CDMO total market by region & country, CAGR, 2021-2032, (USD Million)

U.S. VS China: Formulation Development CDMO total market, key domestic companies, and share, (USD Million)

Global Formulation Development CDMO revenue by player, revenue and market share 2021-2026, (USD Million)

Global Formulation Development CDMO total market by Type, CAGR, 2021-2032, (USD Million)

Global Formulation Development CDMO total market by Application, CAGR, 2021-2032, (USD Million)

This report profiles major players in the global Formulation Development CDMO market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Lonza, Ascendia Pharmaceutical Solutions, Catalent, Cambrex, Ser?n Bioscience, Singota Solutions, Adragos Pharma, Meribel Pharma, Eurofins CDMO, Skyepharma, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Formulation Development CDMO market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US\$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.

Global Formulation Development CDMO Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

Global Formulation Development CDMO Market, Segmentation by Type:

Oral Solid Dosage Forms

Injectable Dosage Forms

Transdermal Dosage Forms

Others

Global Formulation Development CDMO Market, Segmentation by Service Period:

3 Months

6 Months

12 Months

24 Months

Others

Global Formulation Development CDMO Market, Segmentation by Application:

Small molecule chemical drugs

Biologics

Cell and gene therapy products

Others

Companies Profiled:

Lonza

Ascendia Pharmaceutical Solutions

Catalent

Cambrex

Ser?n Bioscience

Singota Solutions

Adragos Pharma

Meribel Pharma

Eurofins CDMO

Skyepharma

Siegfried Group

Recipharm

CordenPharma

Thermo Fisher Scientific

Samsung Biologics

AGC Biologics

WuXi AppTec

Pharmaron

Asymchem

Huahai Pharma

Nipro Pharma

CMIC Group

Hovione

Key Questions Answered

1. How big is the global Formulation Development CDMO market?
2. What is the demand of the global Formulation Development CDMO market?
3. What is the year over year growth of the global Formulation Development CDMO market?
4. What is the total value of the global Formulation Development CDMO market?
5. Who are the Major Players in the global Formulation Development CDMO market?
6. What are the growth factors driving the market demand?

Contents

1 SUPPLY SUMMARY

- 1.1 Formulation Development CDMO Introduction
- 1.2 World Formulation Development CDMO Market Size & Forecast (2021 & 2025 & 2032)
- 1.3 World Formulation Development CDMO Total Market by Region (by Headquarter Location)
 - 1.3.1 World Formulation Development CDMO Market Size by Region (2021-2032), (by Headquarter Location)
 - 1.3.2 United States Based Company Formulation Development CDMO Revenue (2021-2032)
 - 1.3.3 China Based Company Formulation Development CDMO Revenue (2021-2032)
 - 1.3.4 Europe Based Company Formulation Development CDMO Revenue (2021-2032)
 - 1.3.5 Japan Based Company Formulation Development CDMO Revenue (2021-2032)
 - 1.3.6 South Korea Based Company Formulation Development CDMO Revenue (2021-2032)
 - 1.3.7 ASEAN Based Company Formulation Development CDMO Revenue (2021-2032)
 - 1.3.8 India Based Company Formulation Development CDMO Revenue (2021-2032)
- 1.4 Market Drivers, Restraints and Trends
 - 1.4.1 Formulation Development CDMO Market Drivers
 - 1.4.2 Factors Affecting Demand
 - 1.4.3 Major Market Trends

2 DEMAND SUMMARY

- 2.1 World Formulation Development CDMO Consumption Value (2021-2032)
- 2.2 World Formulation Development CDMO Consumption Value by Region
 - 2.2.1 World Formulation Development CDMO Consumption Value by Region (2021-2026)
 - 2.2.2 World Formulation Development CDMO Consumption Value Forecast by Region (2027-2032)
- 2.3 United States Formulation Development CDMO Consumption Value (2021-2032)
- 2.4 China Formulation Development CDMO Consumption Value (2021-2032)
- 2.5 Europe Formulation Development CDMO Consumption Value (2021-2032)
- 2.6 Japan Formulation Development CDMO Consumption Value (2021-2032)

- 2.7 South Korea Formulation Development CDMO Consumption Value (2021-2032)
- 2.8 ASEAN Formulation Development CDMO Consumption Value (2021-2032)
- 2.9 India Formulation Development CDMO Consumption Value (2021-2032)

3 WORLD FORMULATION DEVELOPMENT CDMO COMPANIES COMPETITIVE ANALYSIS

- 3.1 World Formulation Development CDMO Revenue by Player (2021-2026)
- 3.2 Industry Rank and Concentration Rate (CR)
 - 3.2.1 Global Formulation Development CDMO Industry Rank of Major Players
 - 3.2.2 Global Concentration Ratios (CR4) for Formulation Development CDMO in 2025
 - 3.2.3 Global Concentration Ratios (CR8) for Formulation Development CDMO in 2025
- 3.3 Formulation Development CDMO Company Evaluation Quadrant
- 3.4 Formulation Development CDMO Market: Overall Company Footprint Analysis
 - 3.4.1 Formulation Development CDMO Market: Region Footprint
 - 3.4.2 Formulation Development CDMO Market: Company Product Type Footprint
 - 3.4.3 Formulation Development CDMO Market: Company Product Application Footprint
- 3.5 Competitive Environment
 - 3.5.1 Historical Structure of the Industry
 - 3.5.2 Barriers of Market Entry
 - 3.5.3 Factors of Competition
- 3.6 Mergers & Acquisitions Activity

4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)

- 4.1 United States VS China: Formulation Development CDMO Revenue Comparison (by Headquarter Location)
 - 4.1.1 United States VS China: Formulation Development CDMO Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
 - 4.1.2 United States VS China: Formulation Development CDMO Revenue Market Share Comparison (2021 & 2025 & 2032)
- 4.2 United States Based Companies VS China Based Companies: Formulation Development CDMO Consumption Value Comparison
 - 4.2.1 United States VS China: Formulation Development CDMO Consumption Value Comparison (2021 & 2025 & 2032)
 - 4.2.2 United States VS China: Formulation Development CDMO Consumption Value Market Share Comparison (2021 & 2025 & 2032)

4.3 United States Based Formulation Development CDMO Companies and Market Share, 2021-2026

4.3.1 United States Based Formulation Development CDMO Companies, Headquarters (States, Country)

4.3.2 United States Based Companies Formulation Development CDMO Revenue, (2021-2026)

4.4 China Based Companies Formulation Development CDMO Revenue and Market Share, 2021-2026

4.4.1 China Based Formulation Development CDMO Companies, Company Headquarters (Province, Country)

4.4.2 China Based Companies Formulation Development CDMO Revenue, (2021-2026)

4.5 Rest of World Based Formulation Development CDMO Companies and Market Share, 2021-2026

4.5.1 Rest of World Based Formulation Development CDMO Companies, Headquarters (Province, Country)

4.5.2 Rest of World Based Companies Formulation Development CDMO Revenue (2021-2026)

5 MARKET ANALYSIS BY TYPE

5.1 World Formulation Development CDMO Market Size Overview by Type: 2021 VS 2025 VS 2032

5.2 Segment Introduction by Type

5.2.1 Oral Solid Dosage Forms

5.2.2 Injectable Dosage Forms

5.2.3 Transdermal Dosage Forms

5.2.4 Others

5.3 Market Segment by Type

5.3.1 World Formulation Development CDMO Market Size by Type (2021-2026)

5.3.2 World Formulation Development CDMO Market Size by Type (2027-2032)

5.3.3 World Formulation Development CDMO Market Size Market Share by Type (2027-2032)

6 MARKET ANALYSIS BY SERVICE PERIOD

6.1 World Formulation Development CDMO Market Size Overview by Service Period: 2021 VS 2025 VS 2032

6.2 Segment Introduction by Service Period

- 6.2.1 3 Months
- 6.2.2 6 Months
- 6.2.3 12 Months
- 6.2.4 24 Months
- 6.2.5 Others

6.3 Market Segment by Service Period

6.3.1 World Formulation Development CDMO Market Size by Service Period (2021-2026)

6.3.2 World Formulation Development CDMO Market Size by Service Period (2027-2032)

6.3.3 World Formulation Development CDMO Market Size Market Share by Service Period (2027-2032)

7 MARKET ANALYSIS BY APPLICATION

7.1 World Formulation Development CDMO Market Size Overview by Application: 2021 VS 2025 VS 2032

7.2 Segment Introduction by Application

- 7.2.1 Small molecule chemical drugs
- 7.2.2 Biologics
- 7.2.3 Cell and gene therapy products
- 7.2.4 Others

7.3 Market Segment by Application

7.3.1 World Formulation Development CDMO Market Size by Application (2021-2026)

7.3.2 World Formulation Development CDMO Market Size by Application (2027-2032)

7.3.3 World Formulation Development CDMO Market Size Market Share by Application (2021-2032)

8 COMPANY PROFILES

8.1 Lonza

8.1.1 Lonza Details

8.1.2 Lonza Major Business

8.1.3 Lonza Formulation Development CDMO Product and Services

8.1.4 Lonza Formulation Development CDMO Revenue, Gross Margin and Market Share (2021-2026)

8.1.5 Lonza Recent Developments/Updates

8.1.6 Lonza Competitive Strengths & Weaknesses

8.2 Ascendia Pharmaceutical Solutions

- 8.2.1 Ascendia Pharmaceutical Solutions Details
- 8.2.2 Ascendia Pharmaceutical Solutions Major Business
- 8.2.3 Ascendia Pharmaceutical Solutions Formulation Development CDMO Product and Services
- 8.2.4 Ascendia Pharmaceutical Solutions Formulation Development CDMO Revenue, Gross Margin and Market Share (2021-2026)
- 8.2.5 Ascendia Pharmaceutical Solutions Recent Developments/Updates
- 8.2.6 Ascendia Pharmaceutical Solutions Competitive Strengths & Weaknesses
- 8.3 Catalent
 - 8.3.1 Catalent Details
 - 8.3.2 Catalent Major Business
 - 8.3.3 Catalent Formulation Development CDMO Product and Services
 - 8.3.4 Catalent Formulation Development CDMO Revenue, Gross Margin and Market Share (2021-2026)
 - 8.3.5 Catalent Recent Developments/Updates
 - 8.3.6 Catalent Competitive Strengths & Weaknesses
- 8.4 Cambrex
 - 8.4.1 Cambrex Details
 - 8.4.2 Cambrex Major Business
 - 8.4.3 Cambrex Formulation Development CDMO Product and Services
 - 8.4.4 Cambrex Formulation Development CDMO Revenue, Gross Margin and Market Share (2021-2026)
 - 8.4.5 Cambrex Recent Developments/Updates
 - 8.4.6 Cambrex Competitive Strengths & Weaknesses
- 8.5 Ser?n Bioscience
 - 8.5.1 Ser?n Bioscience Details
 - 8.5.2 Ser?n Bioscience Major Business
 - 8.5.3 Ser?n Bioscience Formulation Development CDMO Product and Services
 - 8.5.4 Ser?n Bioscience Formulation Development CDMO Revenue, Gross Margin and Market Share (2021-2026)
 - 8.5.5 Ser?n Bioscience Recent Developments/Updates
 - 8.5.6 Ser?n Bioscience Competitive Strengths & Weaknesses
- 8.6 Singota Solutions
 - 8.6.1 Singota Solutions Details
 - 8.6.2 Singota Solutions Major Business
 - 8.6.3 Singota Solutions Formulation Development CDMO Product and Services
 - 8.6.4 Singota Solutions Formulation Development CDMO Revenue, Gross Margin and Market Share (2021-2026)
 - 8.6.5 Singota Solutions Recent Developments/Updates

- 8.6.6 Singota Solutions Competitive Strengths & Weaknesses
- 8.7 Adragos Pharma
 - 8.7.1 Adragos Pharma Details
 - 8.7.2 Adragos Pharma Major Business
 - 8.7.3 Adragos Pharma Formulation Development CDMO Product and Services
 - 8.7.4 Adragos Pharma Formulation Development CDMO Revenue, Gross Margin and Market Share (2021-2026)
 - 8.7.5 Adragos Pharma Recent Developments/Updates
 - 8.7.6 Adragos Pharma Competitive Strengths & Weaknesses
- 8.8 Meribel Pharma
 - 8.8.1 Meribel Pharma Details
 - 8.8.2 Meribel Pharma Major Business
 - 8.8.3 Meribel Pharma Formulation Development CDMO Product and Services
 - 8.8.4 Meribel Pharma Formulation Development CDMO Revenue, Gross Margin and Market Share (2021-2026)
 - 8.8.5 Meribel Pharma Recent Developments/Updates
 - 8.8.6 Meribel Pharma Competitive Strengths & Weaknesses
- 8.9 Eurofins CDMO
 - 8.9.1 Eurofins CDMO Details
 - 8.9.2 Eurofins CDMO Major Business
 - 8.9.3 Eurofins CDMO Formulation Development CDMO Product and Services
 - 8.9.4 Eurofins CDMO Formulation Development CDMO Revenue, Gross Margin and Market Share (2021-2026)
 - 8.9.5 Eurofins CDMO Recent Developments/Updates
 - 8.9.6 Eurofins CDMO Competitive Strengths & Weaknesses
- 8.10 Skyepharma
 - 8.10.1 Skyepharma Details
 - 8.10.2 Skyepharma Major Business
 - 8.10.3 Skyepharma Formulation Development CDMO Product and Services
 - 8.10.4 Skyepharma Formulation Development CDMO Revenue, Gross Margin and Market Share (2021-2026)
 - 8.10.5 Skyepharma Recent Developments/Updates
 - 8.10.6 Skyepharma Competitive Strengths & Weaknesses
- 8.11 Siegfried Group
 - 8.11.1 Siegfried Group Details
 - 8.11.2 Siegfried Group Major Business
 - 8.11.3 Siegfried Group Formulation Development CDMO Product and Services
 - 8.11.4 Siegfried Group Formulation Development CDMO Revenue, Gross Margin and Market Share (2021-2026)

- 8.11.5 Siegfried Group Recent Developments/Updates
- 8.11.6 Siegfried Group Competitive Strengths & Weaknesses
- 8.12 Recipharm
 - 8.12.1 Recipharm Details
 - 8.12.2 Recipharm Major Business
 - 8.12.3 Recipharm Formulation Development CDMO Product and Services
 - 8.12.4 Recipharm Formulation Development CDMO Revenue, Gross Margin and Market Share (2021-2026)
 - 8.12.5 Recipharm Recent Developments/Updates
 - 8.12.6 Recipharm Competitive Strengths & Weaknesses
- 8.13 CordenPharma
 - 8.13.1 CordenPharma Details
 - 8.13.2 CordenPharma Major Business
 - 8.13.3 CordenPharma Formulation Development CDMO Product and Services
 - 8.13.4 CordenPharma Formulation Development CDMO Revenue, Gross Margin and Market Share (2021-2026)
 - 8.13.5 CordenPharma Recent Developments/Updates
 - 8.13.6 CordenPharma Competitive Strengths & Weaknesses
- 8.14 Thermo Fisher Scientific
 - 8.14.1 Thermo Fisher Scientific Details
 - 8.14.2 Thermo Fisher Scientific Major Business
 - 8.14.3 Thermo Fisher Scientific Formulation Development CDMO Product and Services
 - 8.14.4 Thermo Fisher Scientific Formulation Development CDMO Revenue, Gross Margin and Market Share (2021-2026)
 - 8.14.5 Thermo Fisher Scientific Recent Developments/Updates
 - 8.14.6 Thermo Fisher Scientific Competitive Strengths & Weaknesses
- 8.15 Samsung Biologics
 - 8.15.1 Samsung Biologics Details
 - 8.15.2 Samsung Biologics Major Business
 - 8.15.3 Samsung Biologics Formulation Development CDMO Product and Services
 - 8.15.4 Samsung Biologics Formulation Development CDMO Revenue, Gross Margin and Market Share (2021-2026)
 - 8.15.5 Samsung Biologics Recent Developments/Updates
 - 8.15.6 Samsung Biologics Competitive Strengths & Weaknesses
- 8.16 AGC Biologics
 - 8.16.1 AGC Biologics Details
 - 8.16.2 AGC Biologics Major Business
 - 8.16.3 AGC Biologics Formulation Development CDMO Product and Services

8.16.4 AGC Biologics Formulation Development CDMO Revenue, Gross Margin and Market Share (2021-2026)

8.16.5 AGC Biologics Recent Developments/Updates

8.16.6 AGC Biologics Competitive Strengths & Weaknesses

8.17 WuXi AppTec

8.17.1 WuXi AppTec Details

8.17.2 WuXi AppTec Major Business

8.17.3 WuXi AppTec Formulation Development CDMO Product and Services

8.17.4 WuXi AppTec Formulation Development CDMO Revenue, Gross Margin and Market Share (2021-2026)

8.17.5 WuXi AppTec Recent Developments/Updates

8.17.6 WuXi AppTec Competitive Strengths & Weaknesses

8.18 Pharmaron

8.18.1 Pharmaron Details

8.18.2 Pharmaron Major Business

8.18.3 Pharmaron Formulation Development CDMO Product and Services

8.18.4 Pharmaron Formulation Development CDMO Revenue, Gross Margin and Market Share (2021-2026)

8.18.5 Pharmaron Recent Developments/Updates

8.18.6 Pharmaron Competitive Strengths & Weaknesses

8.19 Asymchem

8.19.1 Asymchem Details

8.19.2 Asymchem Major Business

8.19.3 Asymchem Formulation Development CDMO Product and Services

8.19.4 Asymchem Formulation Development CDMO Revenue, Gross Margin and Market Share (2021-2026)

8.19.5 Asymchem Recent Developments/Updates

8.19.6 Asymchem Competitive Strengths & Weaknesses

8.20 Huahai Pharma

8.20.1 Huahai Pharma Details

8.20.2 Huahai Pharma Major Business

8.20.3 Huahai Pharma Formulation Development CDMO Product and Services

8.20.4 Huahai Pharma Formulation Development CDMO Revenue, Gross Margin and Market Share (2021-2026)

8.20.5 Huahai Pharma Recent Developments/Updates

8.20.6 Huahai Pharma Competitive Strengths & Weaknesses

8.21 Nipro Pharma

8.21.1 Nipro Pharma Details

8.21.2 Nipro Pharma Major Business

- 8.21.3 Nipro Pharma Formulation Development CDMO Product and Services
- 8.21.4 Nipro Pharma Formulation Development CDMO Revenue, Gross Margin and Market Share (2021-2026)
- 8.21.5 Nipro Pharma Recent Developments/Updates
- 8.21.6 Nipro Pharma Competitive Strengths & Weaknesses
- 8.22 CMIC Group
 - 8.22.1 CMIC Group Details
 - 8.22.2 CMIC Group Major Business
 - 8.22.3 CMIC Group Formulation Development CDMO Product and Services
 - 8.22.4 CMIC Group Formulation Development CDMO Revenue, Gross Margin and Market Share (2021-2026)
 - 8.22.5 CMIC Group Recent Developments/Updates
 - 8.22.6 CMIC Group Competitive Strengths & Weaknesses
- 8.23 Hovione
 - 8.23.1 Hovione Details
 - 8.23.2 Hovione Major Business
 - 8.23.3 Hovione Formulation Development CDMO Product and Services
 - 8.23.4 Hovione Formulation Development CDMO Revenue, Gross Margin and Market Share (2021-2026)
 - 8.23.5 Hovione Recent Developments/Updates
 - 8.23.6 Hovione Competitive Strengths & Weaknesses

9 INDUSTRY CHAIN ANALYSIS

- 9.1 Formulation Development CDMO Industry Chain
- 9.2 Formulation Development CDMO Upstream Analysis
- 9.3 Formulation Development CDMO Midstream Analysis
- 9.4 Formulation Development CDMO Downstream Analysis

10 RESEARCH FINDINGS AND CONCLUSION

11 APPENDIX

- 11.1 Methodology
- 11.2 Research Process and Data Source
- 11.3 Disclaimer

List Of Tables

LIST OF TABLES

- Table 1. World Formulation Development CDMO Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
- Table 2. World Formulation Development CDMO Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
- Table 3. World Formulation Development CDMO Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
- Table 4. World Formulation Development CDMO Revenue Market Share by Region (2021-2026), (by Headquarter Location)
- Table 5. World Formulation Development CDMO Revenue Market Share by Region (2027-2032), (by Headquarter Location)
- Table 6. Major Market Trends
- Table 7. World Formulation Development CDMO Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
- Table 8. World Formulation Development CDMO Consumption Value by Region (2021-2026) & (USD Million)
- Table 9. World Formulation Development CDMO Consumption Value Forecast by Region (2027-2032) & (USD Million)
- Table 10. World Formulation Development CDMO Revenue by Player (2021-2026) & (USD Million)
- Table 11. Revenue Market Share of Key Formulation Development CDMO Players in 2025
- Table 12. World Formulation Development CDMO Industry Rank of Major Player, Based on Revenue in 2025
- Table 13. Global Formulation Development CDMO Company Evaluation Quadrant
- Table 14. Head Office of Key Formulation Development CDMO Players
- Table 15. Formulation Development CDMO Market: Company Product Type Footprint
- Table 16. Formulation Development CDMO Market: Company Product Application Footprint
- Table 17. Formulation Development CDMO Mergers & Acquisitions Activity
- Table 18. United States VS China Formulation Development CDMO Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
- Table 19. United States VS China Formulation Development CDMO Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
- Table 20. United States Based Formulation Development CDMO Companies, Headquarters (States, Country)

Table 21. United States Based Companies Formulation Development CDMO Revenue, (2021-2026) & (USD Million)

Table 22. United States Based Companies Formulation Development CDMO Revenue Market Share (2021-2026)

Table 23. China Based Formulation Development CDMO Companies, Headquarters (Province, Country)

Table 24. China Based Companies Formulation Development CDMO Revenue, (2021-2026) & (USD Million)

Table 25. China Based Companies Formulation Development CDMO Revenue Market Share (2021-2026)

Table 26. Rest of World Based Formulation Development CDMO Companies, Headquarters (Province, Country)

Table 27. Rest of World Based Companies Formulation Development CDMO Revenue (2021-2026) & (USD Million)

Table 28. Rest of World Based Companies Formulation Development CDMO Revenue Market Share (2021-2026)

Table 29. World Formulation Development CDMO Market Size by Type, (USD Million), 2021 & 2025 & 2032

Table 30. World Formulation Development CDMO Market Size Value by Type (2021-2026) & (USD Million)

Table 31. World Formulation Development CDMO Market Size by Type (2027-2032) & (USD Million)

Table 32. World Formulation Development CDMO Market Size by Service Period, (USD Million), 2021 & 2025 & 2032

Table 33. World Formulation Development CDMO Market Size Value by Service Period (2021-2026) & (USD Million)

Table 34. World Formulation Development CDMO Market Size by Service Period (2027-2032) & (USD Million)

Table 35. World Formulation Development CDMO Market Size by Application, (USD Million), 2021 & 2025 & 2032

Table 36. World Formulation Development CDMO Market Size by Application (2021-2026) & (USD Million)

Table 37. World Formulation Development CDMO Market Size by Application (2027-2032) & (USD Million)

Table 38. Lonza Basic Information, Manufacturing Base and Competitors

Table 39. Lonza Major Business

Table 40. Lonza Formulation Development CDMO Product and Services

Table 41. Lonza Formulation Development CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

- Table 42. Lonza Recent Developments/Updates
- Table 43. Lonza Competitive Strengths & Weaknesses
- Table 44. Ascendia Pharmaceutical Solutions Basic Information, Manufacturing Base and Competitors
- Table 45. Ascendia Pharmaceutical Solutions Major Business
- Table 46. Ascendia Pharmaceutical Solutions Formulation Development CDMO Product and Services
- Table 47. Ascendia Pharmaceutical Solutions Formulation Development CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 48. Ascendia Pharmaceutical Solutions Recent Developments/Updates
- Table 49. Ascendia Pharmaceutical Solutions Competitive Strengths & Weaknesses
- Table 50. Catalent Basic Information, Manufacturing Base and Competitors
- Table 51. Catalent Major Business
- Table 52. Catalent Formulation Development CDMO Product and Services
- Table 53. Catalent Formulation Development CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 54. Catalent Recent Developments/Updates
- Table 55. Catalent Competitive Strengths & Weaknesses
- Table 56. Cambrex Basic Information, Manufacturing Base and Competitors
- Table 57. Cambrex Major Business
- Table 58. Cambrex Formulation Development CDMO Product and Services
- Table 59. Cambrex Formulation Development CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 60. Cambrex Recent Developments/Updates
- Table 61. Cambrex Competitive Strengths & Weaknesses
- Table 62. Ser?n Bioscience Basic Information, Manufacturing Base and Competitors
- Table 63. Ser?n Bioscience Major Business
- Table 64. Ser?n Bioscience Formulation Development CDMO Product and Services
- Table 65. Ser?n Bioscience Formulation Development CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 66. Ser?n Bioscience Recent Developments/Updates
- Table 67. Ser?n Bioscience Competitive Strengths & Weaknesses
- Table 68. Singota Solutions Basic Information, Manufacturing Base and Competitors
- Table 69. Singota Solutions Major Business
- Table 70. Singota Solutions Formulation Development CDMO Product and Services
- Table 71. Singota Solutions Formulation Development CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 72. Singota Solutions Recent Developments/Updates
- Table 73. Singota Solutions Competitive Strengths & Weaknesses

- Table 74. Adragos Pharma Basic Information, Manufacturing Base and Competitors
- Table 75. Adragos Pharma Major Business
- Table 76. Adragos Pharma Formulation Development CDMO Product and Services
- Table 77. Adragos Pharma Formulation Development CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 78. Adragos Pharma Recent Developments/Updates
- Table 79. Adragos Pharma Competitive Strengths & Weaknesses
- Table 80. Meribel Pharma Basic Information, Manufacturing Base and Competitors
- Table 81. Meribel Pharma Major Business
- Table 82. Meribel Pharma Formulation Development CDMO Product and Services
- Table 83. Meribel Pharma Formulation Development CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 84. Meribel Pharma Recent Developments/Updates
- Table 85. Meribel Pharma Competitive Strengths & Weaknesses
- Table 86. Eurofins CDMO Basic Information, Manufacturing Base and Competitors
- Table 87. Eurofins CDMO Major Business
- Table 88. Eurofins CDMO Formulation Development CDMO Product and Services
- Table 89. Eurofins CDMO Formulation Development CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 90. Eurofins CDMO Recent Developments/Updates
- Table 91. Eurofins CDMO Competitive Strengths & Weaknesses
- Table 92. Skyepharma Basic Information, Manufacturing Base and Competitors
- Table 93. Skyepharma Major Business
- Table 94. Skyepharma Formulation Development CDMO Product and Services
- Table 95. Skyepharma Formulation Development CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 96. Skyepharma Recent Developments/Updates
- Table 97. Skyepharma Competitive Strengths & Weaknesses
- Table 98. Siegfried Group Basic Information, Manufacturing Base and Competitors
- Table 99. Siegfried Group Major Business
- Table 100. Siegfried Group Formulation Development CDMO Product and Services
- Table 101. Siegfried Group Formulation Development CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 102. Siegfried Group Recent Developments/Updates
- Table 103. Siegfried Group Competitive Strengths & Weaknesses
- Table 104. Recipharm Basic Information, Manufacturing Base and Competitors
- Table 105. Recipharm Major Business
- Table 106. Recipharm Formulation Development CDMO Product and Services
- Table 107. Recipharm Formulation Development CDMO Revenue, Gross Margin and

Market Share (2021-2026) & (USD Million)

Table 108. Recipharm Recent Developments/Updates

Table 109. Recipharm Competitive Strengths & Weaknesses

Table 110. CordenPharma Basic Information, Manufacturing Base and Competitors

Table 111. CordenPharma Major Business

Table 112. CordenPharma Formulation Development CDMO Product and Services

Table 113. CordenPharma Formulation Development CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 114. CordenPharma Recent Developments/Updates

Table 115. CordenPharma Competitive Strengths & Weaknesses

Table 116. Thermo Fisher Scientific Basic Information, Manufacturing Base and Competitors

Table 117. Thermo Fisher Scientific Major Business

Table 118. Thermo Fisher Scientific Formulation Development CDMO Product and Services

Table 119. Thermo Fisher Scientific Formulation Development CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 120. Thermo Fisher Scientific Recent Developments/Updates

Table 121. Thermo Fisher Scientific Competitive Strengths & Weaknesses

Table 122. Samsung Biologics Basic Information, Manufacturing Base and Competitors

Table 123. Samsung Biologics Major Business

Table 124. Samsung Biologics Formulation Development CDMO Product and Services

Table 125. Samsung Biologics Formulation Development CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 126. Samsung Biologics Recent Developments/Updates

Table 127. Samsung Biologics Competitive Strengths & Weaknesses

Table 128. AGC Biologics Basic Information, Manufacturing Base and Competitors

Table 129. AGC Biologics Major Business

Table 130. AGC Biologics Formulation Development CDMO Product and Services

Table 131. AGC Biologics Formulation Development CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 132. AGC Biologics Recent Developments/Updates

Table 133. AGC Biologics Competitive Strengths & Weaknesses

Table 134. WuXi AppTec Basic Information, Manufacturing Base and Competitors

Table 135. WuXi AppTec Major Business

Table 136. WuXi AppTec Formulation Development CDMO Product and Services

Table 137. WuXi AppTec Formulation Development CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 138. WuXi AppTec Recent Developments/Updates

- Table 139. WuXi AppTec Competitive Strengths & Weaknesses
- Table 140. Pharmaron Basic Information, Manufacturing Base and Competitors
- Table 141. Pharmaron Major Business
- Table 142. Pharmaron Formulation Development CDMO Product and Services
- Table 143. Pharmaron Formulation Development CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 144. Pharmaron Recent Developments/Updates
- Table 145. Pharmaron Competitive Strengths & Weaknesses
- Table 146. Asymchem Basic Information, Manufacturing Base and Competitors
- Table 147. Asymchem Major Business
- Table 148. Asymchem Formulation Development CDMO Product and Services
- Table 149. Asymchem Formulation Development CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 150. Asymchem Recent Developments/Updates
- Table 151. Asymchem Competitive Strengths & Weaknesses
- Table 152. Huahai Pharma Basic Information, Manufacturing Base and Competitors
- Table 153. Huahai Pharma Major Business
- Table 154. Huahai Pharma Formulation Development CDMO Product and Services
- Table 155. Huahai Pharma Formulation Development CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 156. Huahai Pharma Recent Developments/Updates
- Table 157. Huahai Pharma Competitive Strengths & Weaknesses
- Table 158. Nipro Pharma Basic Information, Manufacturing Base and Competitors
- Table 159. Nipro Pharma Major Business
- Table 160. Nipro Pharma Formulation Development CDMO Product and Services
- Table 161. Nipro Pharma Formulation Development CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 162. Nipro Pharma Recent Developments/Updates
- Table 163. Nipro Pharma Competitive Strengths & Weaknesses
- Table 164. CMIC Group Basic Information, Manufacturing Base and Competitors
- Table 165. CMIC Group Major Business
- Table 166. CMIC Group Formulation Development CDMO Product and Services
- Table 167. CMIC Group Formulation Development CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 168. CMIC Group Recent Developments/Updates
- Table 169. CMIC Group Competitive Strengths & Weaknesses
- Table 170. Hovione Basic Information, Manufacturing Base and Competitors
- Table 171. Hovione Major Business
- Table 172. Hovione Formulation Development CDMO Product and Services

Table 173. Hovione Formulation Development CDMO Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 174. Hovione Recent Developments/Updates

Table 175. Hovione Competitive Strengths & Weaknesses

Table 176. Global Key Players of Formulation Development CDMO Upstream (Raw Materials)

Table 177. Global Formulation Development CDMO Typical Customers

List Of Figures

LIST OF FIGURES

Figure 1. Formulation Development CDMO Picture

Figure 2. World Formulation Development CDMO Total Revenue: 2021 & 2025 & 2032, (USD Million)

Figure 3. World Formulation Development CDMO Total Revenue (2021-2032) & (USD Million)

Figure 4. World Formulation Development CDMO Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)

Figure 5. World Formulation Development CDMO Revenue Market Share by Region (2021-2032), (by Headquarter Location)

Figure 6. United States Based Company Formulation Development CDMO Revenue (2021-2032) & (USD Million)

Figure 7. China Based Company Formulation Development CDMO Revenue (2021-2032) & (USD Million)

Figure 8. Europe Based Company Formulation Development CDMO Revenue (2021-2032) & (USD Million)

Figure 9. Japan Based Company Formulation Development CDMO Revenue (2021-2032) & (USD Million)

Figure 10. South Korea Based Company Formulation Development CDMO Revenue (2021-2032) & (USD Million)

Figure 11. ASEAN Based Company Formulation Development CDMO Revenue (2021-2032) & (USD Million)

Figure 12. India Based Company Formulation Development CDMO Revenue (2021-2032) & (USD Million)

Figure 13. Formulation Development CDMO Market Drivers

Figure 14. Factors Affecting Demand

Figure 15. World Formulation Development CDMO Consumption Value (2021-2032) & (USD Million)

Figure 16. World Formulation Development CDMO Consumption Value Market Share by Region (2021-2032)

Figure 17. United States Formulation Development CDMO Consumption Value (2021-2032) & (USD Million)

Figure 18. China Formulation Development CDMO Consumption Value (2021-2032) & (USD Million)

Figure 19. Europe Formulation Development CDMO Consumption Value (2021-2032) & (USD Million)

Figure 20. Japan Formulation Development CDMO Consumption Value (2021-2032) & (USD Million)

Figure 21. South Korea Formulation Development CDMO Consumption Value (2021-2032) & (USD Million)

Figure 22. ASEAN Formulation Development CDMO Consumption Value (2021-2032) & (USD Million)

Figure 23. India Formulation Development CDMO Consumption Value (2021-2032) & (USD Million)

Figure 24. Producer Shipments of Formulation Development CDMO by Player Revenue (\$MM) and Market Share (%): 2025

Figure 25. Global Four-firm Concentration Ratios (CR4) for Formulation Development CDMO Markets in 2025

Figure 26. Global Four-firm Concentration Ratios (CR8) for Formulation Development CDMO Markets in 2025

Figure 27. United States VS China: Formulation Development CDMO Revenue Market Share Comparison (2021 & 2025 & 2032)

Figure 28. United States VS China: Formulation Development CDMO Consumption Value Market Share Comparison (2021 & 2025 & 2032)

Figure 29. World Formulation Development CDMO Market Size by Type, (USD Million), 2021 & 2025 & 2032

Figure 30. World Formulation Development CDMO Market Size Market Share by Type in 2025

Figure 31. Oral Solid Dosage Forms

Figure 32. Injectable Dosage Forms

Figure 33. Transdermal Dosage Forms

Figure 34. Others

Figure 35. World Formulation Development CDMO Market Size Market Share by Type (2021-2032)

Figure 36. World Formulation Development CDMO Market Size by Service Period, (USD Million), 2021 & 2025 & 2032

Figure 37. World Formulation Development CDMO Market Size Market Share by Service Period in 2025

Figure 38. 3 Months

Figure 39. 6 Months

Figure 40. 12 Months

Figure 41. 24 Months

Figure 42. Others

Figure 43. World Formulation Development CDMO Market Size Market Share by Service Period (2021-2032)

Figure 44. World Formulation Development CDMO Market Size by Application, (USD Million), 2021 & 2025 & 2032

Figure 45. World Formulation Development CDMO Market Size Market Share by Application in 2025

Figure 46. Small molecule chemical drugs

Figure 47. Biologics

Figure 48. Cell and gene therapy products

Figure 49. Others

Figure 50. World Formulation Development CDMO Market Size Market Share by Application (2021-2032)

Figure 51. Formulation Development CDMO Industrial Chain

Figure 52. Methodology

Figure 53. Research Process and Data Source

I would like to order

Product name: Global Formulation Development CDMO Supply, Demand and Key Producers, 2026-2032

Product link: <https://marketpublishers.com/r/G494E27FD56EEN.html>

Price: US\$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G494E27FD56EEN.html>